Nasal Delivery Market Scope
Nasal delivery is an administration of a drug through nasal route for the treatment of local infection in the nasal course & paranasal sinuses such as allergic & non-allergic sinusitis & rhinitis. The nasal drug delivery technology is used to reduce the problems like less bioavailability of drug and slow absorption of drugs. Nasal drug delivery is very helpful for patients having gastrointestinal problems.
According to AMA, the Global Nasal Delivery market is expected to see growth rate of 6.3%
Research Analyst at AMA estimates that United Kingdom, United States Players will contribute to the maximum growth of Global Nasal Delivery market throughout the predicted period.
Merck & Co. Inc. (United States), Novartis AG (Switzerland), Johnson & Johnson (United States), Pfizer Inc. (United States), AstraZeneca (United Kingdom), AptarGroup Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Aegis Therapeutics LLC. (United States), Becton, Dickinson and Company (United States), Sisecam Group (Bulgaria), Teleflex Medical Europe Ltd (Ireland) and Procter & Gamble (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Bespak Europe Ltd (United Kingdom), Kurve Technology Inc. (United States), Nemera, AptarGroup Inc. (France), Curida AS (Norway), SMC Ltd (United States), Meroven Pharmaceuticals Ltd. (Australia), Mystic Pharmaceuticals (United States) and MedPharmand (United Kingdom).
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.
The study have segmented the market of Global Nasal Delivery market and Region with country level break-up.
On the basis of geography, the market of Nasal Delivery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Leaders and their expansionary development strategies
On 3 Dec 2018, Neurelis, Inc. has announced the acquisition of Aegis Therapeutics, a San Diego-based drug delivery technology company. Aegis Therapeutics' proprietary portfolio includes Intravail, ProTek and Hydrogel, three non-invasive drug delivery and stabilization technologies applicable to a wide range of molecules including therapeutic proteins, peptides, non-peptide macromolecules, and small molecules.
On 2 Oct 2018, Aptar Pharma has launched PureHale, a new portable and ready-to-use delivery solution designed for upper respiratory care. PureHale is a revolutionary and intuitive device which when used in combination with saline or other natural ingredient formulations assists relieve the symptoms of upper respiratory system conditions.
- Increasing Patient Preference for Nasal Drug Delivery as Easy Administration.
- Increasing Emphasis on Pediatric and Geriatric Population
- Better Efficacy and Better Bioavailability.
- Increasing Cases of Chronic Diseases
- Emerging Demand from Economies
- Complications of Overdose of Nasal Route of Administration
- Increasing Options for Other Route of Administrations
- Stumbling Block of Nasal Route of Administration
Key Target AudienceNasal Drug Delivery Manufacturers, Public and Private Physicians, Healthcare Institutions (Medical Data Centers), Research & Clinical Laboratories, Distributors and Suppliers of Nasal Drug Delivery Technologies, Health Insurance Payers and Market Research and Consulting Firms